Skip to main content

In the News

Science & Technology | Study Illuminates K-Ras4B Activation, Which May Help Predict Drug Resistance

Until recently, researchers studying RAS, a family of proteins involved in transmitting signals within cells, believed that the exchange of guanosine 5’-diphosphate (GDP) by guanosine triphosphate (GTP) was sufficient to activate the protein. Once activated, RAS can cause unintended and overactive signaling in cells, which can lead to cell division and, ultimately, cancer.

Community | Johns Hopkins University Announces Frederick CREST Classes for Fall 2016

Johns Hopkins University’s (JHU) Advanced Academic Programs (AAP) division recently announced two classes that will be hosted at the Frederick Center for Research and Education in Science and Technology (CREST) this fall. According to a JHU press release, the classes are Biochemistry, which is part of the M.S. in Biotechnology program at JHU AAP, and Molecular Biology, a part of the M.S. in Bioinformatics program at JHU AAP.

Events | OHS Encourages People to Hike Despite the Heat

Even the blazing heat could not stop people from enjoying the Occupational Health Services’ (OHS) most recent Take a Hike event, which promoted healthy living. The red, white, and blue–themed, 1.3-mile walk was the fifth such event since 2014 for NCI at Frederick. People got out of their offices to exercise, show off their patriotism, and win prizes.

Science & Technology | Students Become Scientists at Science Skills Boot Camp

At the 2016 Science Skills Boot Camp (SSBC), a one-day training program designed for NIH summer interns with little or no prior research experience, students gathered to learn about basic research and laboratory skills. The boot camp provided a unique opportunity for interns to expand their knowledge of simple bench techniques, scientific papers, and ways to communicate their research.

Awards | Federal Laboratory Consortium Recognizes Unituxin Collaborators with Excellence in Technology Transfer Awards

The Federal Laboratory Consortium (FLC) presented an Excellence in Technology Transfer award to the group that collaborated to bring Unituxin (dinutuximab, also known as ch14.18), an immunotherapy for neuroblastoma, to licensure.